Evidence map›Paper›PMID 24068931›Full record

ArticlePLoS pathogens2013

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Rogier W Sanders, Ronald Derking, Albert Cupo, Jean-Philippe Julien, Anila Yasmeen, Natalia de Val, Helen J Kim, Claudia Blattner, Alba Torrents de la Peña, Jacob Korzun and 9 more

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03783130 (VRC 018), which is not on this map. Cited by 767 papers.

0numbers the graph read from it
0cells of the map it votes in
767citing papers in PubMed
26.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03783130 phase1completednot on this mapstarted 2019, after this paper: background citation

VRC 018: A Phase I Dose Escalation, Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2020Enrolled16ConditionsHuman Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)ArmsVRC-HIVRGP096-00-VP, Alum Adjuvant
3 · Its place in the literature

Who cites it

767 citing papers in PubMed, 993 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

707 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Rogier W SandersDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America ; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Ronald Derking
Albert Cupo
Jean-Philippe Julien
Anila Yasmeen
Natalia de Val
Helen J Kim
Claudia Blattner
Alba Torrents de la Peña
Jacob Korzun
Michael Golabek
Kevin de Los Reyes
Thomas J Ketas
Marit J van Gils
C Richter King
Ian A Wilson
Andrew B Ward
P J Klasse
John P Moore
Cornell University · USInternational AIDS Vaccine Initiative · USAcademic Medical Center · NLScripps Research Institute · USUniversity of Amsterdam · NL

Funding

Trimer Production and Immunogenicity TestingP01AI082362 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2009 to 2014
$16.0M
TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2012 to 2021
$14.7M
WORKSHOPS AND TRAININGP41RR017573 · NCRR · SCRIPPS RESEARCH INSTITUTE, THE · PI CARRAGHER, BRIDGET OLIVIA · 2002 to 2011
$14.2M
NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
CIHRNCRR NIH HHS P41 RR017573NCRR NIH HHS RR017573NIAID NIH HHS P01 AI082362NIAID NIH HHS P01 AI82362NIAID NIH HHS R37 AI036082NIAID NIH HHS R37 AI36082NIGMS NIH HHS P41 GM103310
6 · The paper itself

Abstract

A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One approach to the problem is to create trimeric mimics of the native envelope glycoprotein (Env) spike that expose as many bNAb epitopes as possible, while occluding those for non-neutralizing antibodies (non-NAbs). Here, we describe the design and properties of soluble, cleaved SOSIP.664 gp140 trimers based on the subtype A transmitted/founder strain, BG505. These trimers are highly stable, more so even than the corresponding gp120 monomer, as judged by differential scanning calorimetry. They are also homogenous and closely resemble native virus spikes when visualized by negative stain electron microscopy (EM). We used several techniques, including ELISA and surface plasmon resonance (SPR), to determine the relationship between the ability of monoclonal antibodies (MAbs) to bind the soluble trimers and neutralize the corresponding virus. In general, the concordance was excellent, in that virtually all bNAbs against multiple neutralizing epitopes on HIV-1 Env were highly reactive with the BG505 SOSIP.664 gp140 trimers, including quaternary epitopes (CH01, PG9, PG16 and PGT145). Conversely, non-NAbs to the CD4-binding site, CD4-induced epitopes or gp41ECTO did not react with the trimers, even when their epitopes were present on simpler forms of Env (e.g. gp120 monomers or dissociated gp41 subunits). Three non-neutralizing MAbs to V3 epitopes did, however, react strongly with the trimers but only by ELISA, and not at all by SPR and to only a limited extent by EM. These new soluble trimers are useful for structural studies and are being assessed for their performance as immunogens.

Indexed as

EpitopesAIDS VaccinesAmino Acid SubstitutionAntibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityAntibody Specificityenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansImmunoglobulin Fab FragmentsMolecular WeightMutant ProteinsPeptide FragmentsAIDS VaccinesAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesImmunoglobulin Fab FragmentsMutant ProteinsPeptide FragmentsProtein AggregatesRecombinant Fusion Proteins

Identifiers

PMID24068931
PMCPMC3777863
OpenAlexW2083002978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.